Labiana Health S.A. Asset Resilience Ratio
Labiana Health S.A. asset resilience ratio. Labiana Health S.A. (LAB) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LAB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Labiana Health S.A. (2021–2025)
Asset resilience ratio of Labiana Health S.A. from 2021 to 2025. This chart shows how Labiana Health S.A.'s Asset Resilience Ratio has changed over time. Read Labiana Health S.A. debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Labiana Health S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Labiana Health S.A. total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.80K | 0.0% |
| Total Liquid Assets | €1.80K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Labiana Health S.A. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Labiana Health S.A. Industry Peers by Asset Resilience Ratio
Compare Labiana Health S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Labiana Health S.A. Asset Resilience Ratio by Year (2021–2025)
Labiana Health S.A. asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Labiana Health S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €1.80K ≈ $2.10K |
€57.54 Million ≈ $67.27 Million |
+0.00pp |
| 2024-12-31 | 0.00% | €800.25 ≈ $935.58 |
€52.00 Million ≈ $60.80 Million |
-0.02pp |
| 2023-12-31 | 0.02% | €13.94K ≈ $16.30K |
€59.12 Million ≈ $69.12 Million |
-4.16pp |
| 2022-12-31 | 4.19% | €2.54 Million ≈ $2.97 Million |
€60.78 Million ≈ $71.06 Million |
+4.17pp |
| 2021-12-31 | 0.02% | €11.45K ≈ $13.38K |
€68.37 Million ≈ $79.93 Million |
-- |
About Labiana Health S.A.
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage f… Read more